Valeant Pharmaceuticals, the largest obligor across US CLOs, announced a loss for the second quarter on Tuesday, but its CEO reassured investors and lenders that the plan for a turnaround is still on track.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Sam Kerr